Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLUE 
Monte Rosa Therapeutics Inc (GLUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: GLUE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.71
1 Year Target Price $15.71
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.49% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 427.99M USD | Price to earnings Ratio 17.77 | 1Y Target Price 15.71 |
Price to earnings Ratio 17.77 | 1Y Target Price 15.71 | ||
Volume (30-day avg) 9 | Beta 1.42 | 52 Weeks Range 3.50 - 12.40 | Updated Date 09/16/2025 |
52 Weeks Range 3.50 - 12.40 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.58% | Operating Margin (TTM) -67.06% |
Management Effectiveness
Return on Assets (TTM) 2.66% | Return on Equity (TTM) 9.81% |
Valuation
Trailing PE 17.77 | Forward PE 10.02 | Enterprise Value 47599473 | Price to Sales(TTM) 2.4 |
Enterprise Value 47599473 | Price to Sales(TTM) 2.4 | ||
Enterprise Value to Revenue 0.27 | Enterprise Value to EBITDA 2.04 | Shares Outstanding 61759400 | Shares Floating 30303460 |
Shares Outstanding 61759400 | Shares Floating 30303460 | ||
Percent Insiders 0.73 | Percent Institutions 100.42 |
Upturn AI SWOT
Monte Rosa Therapeutics Inc
Company Overview
History and Background
Monte Rosa Therapeutics was founded in 2018 and is focused on developing small molecule protein degraders to treat diseases. The company aims to leverage its QuEEN (Quaternary Encoding of Endogenous Neosubstrates) platform to identify and develop novel degrader therapies.
Core Business Areas
- Protein Degradation Therapeutics: Monte Rosa focuses on discovering and developing small molecule protein degraders, specifically targeting proteins that are difficult to address with traditional drug modalities.
- QuEEN Platform: Utilizing its proprietary QuEEN platform to identify neo-substrates and develop targeted protein degradation therapies.
Leadership and Structure
The leadership team includes experienced executives in drug discovery and development. The organizational structure consists of research and development teams focused on advancing its pipeline.
Top Products and Market Share
Key Offerings
- MRT-2359 (GSPT1 degrader): MRT-2359 is a GSPT1 (translation termination factor GTPase) degrader being developed for MYC-driven cancers. Phase 1/2 clinical trials are underway. Competitors include companies developing other MYC-targeting therapies. Market share data not publicly available.
- Degrader Pipeline: Monte Rosa has a pipeline of preclinical degrader programs targeting various disease areas. Market share and revenue data are not applicable for preclinical programs.
Market Dynamics
Industry Overview
The protein degradation field is a rapidly growing area of drug development, with increasing interest from pharmaceutical companies and venture capital firms. The space involves novel therapies for diverse diseases, especially cancer.
Positioning
Monte Rosa Therapeutics is positioned as a leader in developing small molecule protein degraders using its QuEEN platform. Its competitive advantage lies in its unique platform and targeted approach to protein degradation.
Total Addressable Market (TAM)
The TAM for protein degradation therapies is potentially very large, covering a wide range of diseases. The specific TAM for Monte Rosa's targets will depend on clinical success and market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary QuEEN platform
- Experienced leadership team
- Strong intellectual property position
- Focus on a novel drug modality
Weaknesses
- Early-stage pipeline
- High cash burn rate
- Dependence on successful clinical trials
- Risk associated with novel technology
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to new targets
- Positive clinical trial results
- Increased investor interest in protein degradation
Threats
- Clinical trial failures
- Competition from other protein degradation companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- KYMR
- ARRY
- CRBN
Competitive Landscape
Monte Rosa's advantage lies in its proprietary QuEEN platform, but it faces competition from other companies developing protein degradation therapies with varying approaches. GLUE is an early player with a unique approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily related to pipeline development and preclinical progress.
Future Projections: Future growth is dependent on clinical trial success and potential partnerships.
Recent Initiatives: Focus on advancing MRT-2359 into later-stage clinical trials and expanding the preclinical pipeline.
Summary
Monte Rosa Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of molecular glues that selectively degrade disease-causing proteins. The company's QuEEN platform has attracted interest, but success relies on clinical validation. Its high cash burn rate is also a concern and competition in protein degradation space should be monitored.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monte Rosa Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-06-24 | President, CEO & Director Dr. Markus Warmuth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 142 | Website https://www.monterosatx.com |
Full time employees 142 | Website https://www.monterosatx.com | ||
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.